INDEX

ADVERTISING
low tar cigarettes, 371-372

AGE FACTORS
arterial disease prevalence, 183-184
atherosclerosis and smoking relationship, 32
atherosclerosis, aortic aneurysm, and smoking relationship, 194
cardiovascular disease mortality trends, 331
cerebrovascular disease risk, 5, 8
cessation attempts, 10-11, 370, 373
CHD mortality, 7, 113, 128, 369, 362, 364
CHD relationship, 75-76, 91, 92, 101-102, 133-134
daily cigarette consumption, 10, 367, 373
intermittent claudication prevalence, 184
prevalence of smoking, 10, 259, 365-366, 373
stroke incidence, 165-166, 171
stroke mortality trends, 341

ALCOHOL CONSUMPTION
CHD mortality relationship, 111-112
CHD relationship, 68, 91
coronary calcification relationship, 32
lipoprotein level relationship, 96
stroke risk factor, 162
sudden cardiac death relationship, 104-105

ALLERGY
tobacco allergy and cardiovascular effects, 66-66, 186-189

AMISH
mortality, 126-127

AMPUTATION
healing failure and smoking, 192

ANGINA PECTORIS—Contd.
carbonyhemoglobin level, 223
CHD manifestation, 67, 70-71
incidence in Belfast, 84
incidence in smokers with CHD, 213
risk in female smokers, 102
smoking relationship, 70, 77, 86-87

AORTA
aneurysm diagnosis, 192
aneurysm prevalence in smokers and nonsmokers, 45
atherosclerosis and nicotine exposure, 50
atherosclerosis and smoking, 22, 34, 46-48, 56
atherosclerosis as cause, 16
atherosclerosis development, 5, 18
epidemiologic data, 194-195
mortality trends, 341
tobacco smoke effects in rats, 53

ARTERIOSCLEROSIS
See also Atherosclerosis
angina pectoris relationship, 70
carbon disulfide exposure relationship, 226
cardiovascular disease causation, 5
definition, 15
mortality trends, 341
percent attributable to smoking, 65
underlying process of stroke, 340

ATHEROMA
definition, 15
small arteries of myocardium, 34

ATHEROSCLEROSIS
See also Arteriosclerosis
age and smoking relationship, 194
aortic aneurysm relationship, 192
atherogenesis, 19-21
cadmium exposure relationship, 227
carbon monoxide exposure relationship, 223
cardiac arrest, 69
cardiovascular disease causation, 5
ATHEROSCLEROSIS—Contd.
clinical significance, 16-17
definition, 15-16
dietary cholesterol effect, 100
epidemiologic studies, 21-48
incidence in smokers and nonsmokers, 67
literature reviews, 17
mortality and smoking, 229
natural history, 17-19
nicotine effects, 216
pathophysiologic mechanisms of tobacco smoke, 48, 50-54
plasma triglyceride correlation, 181
risk factors, 205-206
severity trends, 343-344
smoking cessation effects, 5
smoking effects, 5-6
topographic distribution, 18

BLOOD FLOW
nicotine and tobacco smoke effects, 189
nicotine effects, 215
smoking relationship, 187-188

BLOOD PRESSURE
(See also HYPERTENSION)
CHD risk factor, 97-98, 108, 130, 194
coronary atherosclerosis relationship, 33
intermittent claudication relationship, 184
intervention trial effects, 315, 317
intervention trial for single risk factor, 300
nicotine effects, 3, 215
race factors, 77
smoking cessation relationship, 96-97
smoking relationship, 55, 96-97, 187-188

BLOOD FLOW
nicotine and tobacco smoke effects, 189
nicotine effects, 215
smoking relationship, 187-188

BLOOD PRESSURE
(See also HYPERTENSION)
CHD risk factor, 97-98, 108, 130, 194
coronary atherosclerosis relationship, 33
intermittent claudication relationship, 184
intervention trial effects, 315, 317
intervention trial for single risk factor, 300
nicotine effects, 3, 215
race factors, 77
smoking cessation relationship, 96-97
smoking relationship, 55, 96-97, 187-188

BODY FAT
CHD risk factors, 132

BODY WEIGHT
(See also OBESITY)
smokers versus nonsmokers, 55
smoking effect in baboons, 190
stroke incidence relationship, 163
sudden cardiac death risk factor, 104

CADMIUM
physiological effects, 226-227
tobacco smoke constituent, 226

Cancer See NEOPLASMS
CARBON DISULFIDE
atherosclerotic diseases, as risk factor, 226

CARBON MONOXIDE
atherogenic effects, 5, 51-52
blood levels in smoking baboons, 190
cardiovascular disease relationship, 220, 222-224
cardiovascular effects, 220
chemistry, 219-220
effects of cigarette smoking, 186
fibrinolysis relationship, 187
myocardial infarction risk, 229
platelet adhesiveness relationship, 189-190
steelworkers' exposure and CHD mortality, 111
toxicologic effects, 9
validation of self-reported smoking cessation, 245, 261

CARBONYL SULFIDE
atherogenic effects, 225
catecholamines See EPINEPHRINE; NOREPINEPHRINE

CENTRAL NERVOUS SYSTEM
nicotine effects, 213

CEREBROVASCULAR DISEASE
(See also STROKE)
atherosclerosis of cerebral vasculature, 48
cerebral thrombosis incidence, 344
cessation of smoking relationship, 168
demographic trends, 344
morbidity and mortality, 158-160
mortality trends, 329, 340
oral contraceptives relationship, 168-171
prevention, 170
risk factors, 160-162, 168-171
smoking as risk factor, 5, 8, 162-166
subarachnoid hemorrhage, 5, 8, 167
transient ischemic attacks, 166-167

CESSATION OF SMOKING
(See also EX-SMOKE, REDUCTION OF SMOKING; SMOKING INTERVENTION TRIALS)
Attempts to quit, 10-11, 369-370, 373
blood pressure correlation, 96-97

INDEX
INDEX

**CESSATION OF SMOKING—Contd.**
- CHD epidemiology, 243–283, 300–321
- CHD mortality rates, 8–10, 122–126, 128, 293–321
- definition in intervention trials, 246–247
- following cardiovascular events, 213, 215
- peripheral vascular disease treatment, 5, 8, 179, 190, 192, 194
- peripheral vascular effects, 187–188
- stroke mortality risk, 168
- stroke prevention, 170
- sudden cardiac death risk, 7, 105
- validation of self-reports, 244–246, 258, 261, 265, 279–280, 305, 312

**CHEWING TOBACCO**
- intermittent claudication relationship, 186

**CHOLESTEROL**
- (See also DIET; LIPIDS; LIPOPROTEINS)
  - aortic tissue levels following smoke exposure, 219
  - atherogenesis relationship, 19–20, 50–54, 216–217
  - atherosclerosis and diet in rabbits, 189–191
  - carbon monoxide, diet, and atherosclerosis, 223
  - cardiovascular disease risk and blood levels, 205
  - CHD risk, 5, 7, 89, 91–93, 96–100, 127, 129–130, 136, 344
  - coronary atherosclerosis and serum levels, 53
  - hypercholesterolemia prevalence, 346
  - intermittent claudication and serum levels, 184
  - intervention trial effects, 312–313, 315, 317
  - intervention trials for single risk factor, 300
  - myocardial infarction and serum levels, 165
  - peripheral vascular disease relationship, 180–182, 184
- smoking and blood levels, 188, 224
- smoking and serum levels, 6, 56, 182
- stroke risk predictor, 161
- sudden cardiac death and serum levels, 104

**CHRONIC OBSTRUCTIVE PULMONARY DISEASE**
- (See also EMPHYSEMA)
- mortality trends, 333, 338–340

**CIGAR SMOKERS**
- aortic lesions, 194
- CHD mortality, 8, 122
- CHD risk, 86, 128
- coronary event risk, 76–77
- former cigarette smokers, 252
- inhalation avoidance, 212
- myocardial infarction risk, 88
- peripheral vascular disease risk, 191
- stroke mortality, 163
- thiocyanate elevation, 244

**COFFEE CONSUMPTION**
- blood lipid effects, 182
- CHD risk factor, 91, 97
- stroke risk factor, 162

**CORONARY ARTERIES**
- atherosclerosis in, 18
- atherosclerotic lesions after nicotine exposure, 50
- carbon monoxide effect on lipid metabolism in, 52
- smoking and atherosclerosis in, 22–34, 56

**CORONARY HEART DISEASE**
- (See also MYOCARDIAL INFARCTION)
- age factors in smoking effect, 112–113, 116–117, 120
- atherosclerosis as underlying cause, 16
- cessation of smoking and epidemiology, 5–6, 10, 122–126, 128, 293–321
- clinical manifestations, 67–71
- death certificate ascertainment, 69–70
- incidence studies, 342–343
- intervention trial effects on incidence, 9
- low risk populations, 126–127
- low yield cigarettes, 120–122, 128
INDEX

CORONARY HEART DISEASE—Contd. DIET—Contd.
mortality trends, 329, 334, 336, 338-340, 348-352
pipe and cigar smokers, 122, 128
prevalence trends, 3
prospective cohort studies, 105-113
risk assessment, 129-136
risk factor reduction and mortality trends, 344, 346-348
risk factors, 91-93, 96-97
smoking relationship, 4-8, 65-67, 119, 119, 127, 128
synergism among risk factors, 97-100
treatment improvements, 348
COTININE
cigar smokers' serum, 212
nicotine metabolite, 212-213
serum levels and uptake of particulates, 228
urine concentration in smoking barbons, 190
validation of self-reported cessation, 245
CROSS-CULTURAL STUDIES
atherosclerosis topographic distribution, 18
CHD incidence and mortality, 79-91
Demographic Factors See AGE FACTORS; EDUCATIONAL ATTAINMENT; RACE FACTORS; SEX FACTORS; SOCIOECONOMIC STATUS
DIABETES MELLITUS
atherogenesis relationship, 20
cardiovascular disease risk factor, 236
CHD incidence relationship, 89
CHD risk factor, 91-92
mortality trends, 334
peripheral vascular disease relationship, 179, 183, 185, 191
prevalence, 346
stroke risk factor, 162, 165
DIET
(See also CHOLESTEROL; SATURATED FATS)
atherogenesis correlation, 19-20
CHD mortality relationship, 112
high cholesterol diet, nicotine, and arterial damage, 50
nutritional status and smoking role in atherosclerosis, 33
treatment of peripheral vascular disease, 179
Dose-Response Relationship See SMOKING PATTERNS
DRUG INTERACTIONS
atenolol physiologic effects in smokers, 186
diazepam reactivity in smokers, 222
methacholine effects on norepinephrine, 216
norepinephrine effects of dimethylphenylpiperazinium, 216
oxytremorine effects on norepinephrine, 216
phenacetin reactivity in smokers, 222
propranolol physiologic effects in smokers, 186
EDUCATIONAL ATTAINMENT
cessation attempt frequency relationship, 369
cigarette consumption relationship, 367
ELECTROCARDIOGRAM
abnormalities as stroke risk factor, 162-163, 165
CHD risk prediction, 134
intervention effect, 232
nitrogen dioxide exposure and cardiac function, 226
EMPHYSEMA
(See also CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
cadmium exposure as risk factor, 226
nitrogen oxides exposure as risk factor, 226
smoking relationship, 228
ENZYMES
carbon monoxide affinity, 222-223
EPINEPHRINE
nicotine effects, 213, 215-216
plasma levels and smoking, 186
ERYTHROCYTES
(See also HEMATOCRIT)
counts in smokers, 55
nicotine effects in rabbits, 190
INDEX

EX-SMOKERS
(See also CESSATION OF SMOKING)
aortic lesions, 47, 194
atherosclerosis mortality, 229
CHD incidence, 82
CHD mortality, 5–8, 8
death risk after myocardial infarction or angina, 105
differences from smokers, 297
peripheral arterial disease in women, 185
stroke mortality, 163, 168

FAMILY
wives' participation in intervention trials, 257, 260

FETUS
(See also MATERNAL SMOKING)
maternal cadmium administration effects on fetal brain in rats, 227
maternal smoking effects, 189

FIBRINriger
smoking effects, 55, 187

FIBRINOLOGY
nicotine effects, 218
smoking effects, 55, 197

FILTER CIGARETTES
(See also LOW YIELD CIGARETTES)
carbon monoxide yields, 220
cardiovascular disease incidence, 228
CHD mortality effects, 8
CHD risk, 120
hydrogen cyanide removal, 224–225
nicotine delivery, 210
nitrogen oxide reduction, 225

GLUCOSE
atherosclerosis and blood levels, 218
intermittent claudication and blood levels, 184
intolerance and peripheral vascular disease, 182
smoking and blood levels in baboons, 55, 190

HEART RATE
atherosclerosis correlation, 218
nicotine effects, 3, 215–216
smoking effects, 187

HEIGHT
CHD risk factor, 107
stroke risk factor, 163

HEMATOCRIT
(See also ERYTHROCYTES)
nicotine effects in rabbits, 190
smoking effects, 55, 187

HEMOGLOBIN
carbon monoxide binding, 222
nicotine effects in rabbits, 190
smoking effects, 55, 186–187

HEREDITY
cadmium-induced hypertension, 227
CHD risk factor, 91–92, 108
coronary disease history and platelet activation, 55
stroke risk factor, 166

HORMONES
estrogen and myocardial infarction, 103
nicotine effects on antidiuretic hormone secretion, 213

HYDROGEN CYANIDE
coronary arteries and aorta effects, 52
serum thiocyanate as metabolite, 244
tobacco smoke constituent, 224

HYPERTENSION
(See also BLOOD PRESSURE)
atherogenesis relationship, 20
cadmium level relationship, 226–227
cardiovascular disease risk factor, 205
CHD risk factor, 5, 7, 89, 91–93, 127, 344
educational campaign effects, 348
mortality trends, 329, 341
peripheral vascular disease relationship, 179, 181
prevalence trends, 346
renal artery stenosis, hypertension, and smoking relationship, 185
stroke risk factor, 161–163, 165–166, 170, 340
sudden cardiac death risk factor, 104

IMMUNE SYSTEM
alterations in smokers, 55–56
hypersensitivity and tar exposure, 223

INFLUENZA
mortality trends, 334
INDEX

IN VOLUNTARY SMOKING
atherosclerotic cardiovascular disease etiology, 186
cotinine in urine of nonsmokers, 212–213

KIDNEYS
cadmium localization, 226
nicotine metabolism, 212
renal artery stenosis, hypertension, and smoking interrelationship, 185

LEAD
atherosclerosis and lead in drinking water, 227

LEGISLATION
smoking restrictions in Finland, 279–280, 316

LEUKOCYTES
elevation in smokers, 55–56
nicotine effects, 190

LINOLENIC ACID
CHD incidence and consumption, 86

LIPIDS
(See also CHOLESTEROL)
atherogenesis relationship, 19–21, 52–54, 217–218
carbon monoxide and blood levels, 223–224
dietary cholesterol and serum level, 190
nicotine administration and serum level, 190
race factors and plasma levels, 77
smoking and serum levels, 219
smoking serum levels in baboons, 190

Lipoproteins
atherogenic role, 21
cadmium exposure relationship in pigeons, 227
CHD incidence, 92
hyperlipoproteinemia and atherogenesis, 20
hyperlipoproteinemia and peripheral vascular disease, 180–181
oral contraceptives and smoking effects, 104
race factors, 77
smoking effects, 6, 53, 54, 56, 93, 96, 190, 219
stroke relationship, 161–163

LIVER
cadmium accumulation, 226
cirrhosis mortality trends, 334
lipoprotein metabolism impairment and peripheral vascular disease, 182
nicotine metabolism, 212
protein synthesis and carbon monoxide exposure, 222

LOW YIELD CIGARETTES
(See also FILTER CIGARETTES)
cardiovascular disease relationship, 229–230
CHD mortality effects, 8, 120–122, 128
smoking pattern effects, 9, 210, 218, 230, 272
stroke mortality relationship, 164–165

LUNG CANCER
(See also NEOPLASMS)
deaths in smoking intervention trials, 306, 309
excess deaths attributable to smoking, 65
mortality trends, 333, 338–339

LUNGS
nicotine metabolism, 212

LYMPHOCYTES
smoking effects in baboons, 190

LYSOSOMES
nicotine effects, 219

MASS MEDIA
in smoking intervention trials, 263–264, 270, 272, 278–279, 281–283, 316

MATERNAL SMOKING
(See also FETUS)
umbilical artery changes, 219

MENOPAUSE
CHD risk, 7, 101–104, 127
MORMONS
CHD risk, 7, 101–104, 127

MORTALITY
calculations, 333, 356
cardiovascular disease mortality trends, 329–344
cardiovascular disease risk factor reduction effects, 344–348
cessation of smoking effects, 8–9, 194, 293–321
INDEX

MORTALITY—Contd.
CHD mortality trends, 339–341
coronary care improvement effects, 348
prospective studies of CHD mortality, 106–113
MYOCARDIAL INFARCTION
(See also CORONARY HEART DISEASE)
carbon monoxide exposure correlation, 51
carboxyhemoglobin level relationship, 223
cardiac arrest etiology, 69
case-fatality trends, 344
CHD manifestation, 67
clinical manifestations, 67–68
discharge rate trends, 344
free fatty acid elevation in smokers following myocardial infarction, 219
hyperlipoproteinemia in survivors, 181
incidence, 342–343
mortality trends, 339–340
nicotine and carbon monoxide delivery relationship, 229
oral contraceptive use as risk factor, 7, 128
zinc deficiency correlation, 227
MYOCARDIUM
atherosclerosis of small arteries, 34
MYOGLOBIN
carbon monoxide binding, 222
NEOPLASMS
(See also LUNG CANCER)
cancer death in smoking intervention trial, 306, 310
cancer mortality in Seventh Day Adventists, 126
cerebral neoplasms and stroke, 166
death rates and smoking patterns, 81
respiratory tract cancer mortality and smoking, 81
NICOTINE
atherosclerosis pathogenesis, 5, 48, 50–51
blood flow effects, 189
blood pressure and heart rate effects, 3
cardiovascular effects, 213, 215–219, 230
chemistry, 209–212
fibrinolysis relationship, 187
hematologic effects, 190
metabolism, 212–213
myocardial infarction risk, 229
particulate uptake and serum levels, 228
peripheral vascular effects, 187–188
serum lipid effects, 190
toxicologic effects, 9
validation of self-reported smoking cessation, 245
yields in U.S. cigarettes, 210
NICOTINE CHEWING GUM
smoking intervention, 270
NITROGEN OXIDES
coronary artery and aorta effects of nitric oxide, 52
nitric oxide, carbon monoxide, and atherosclerotic changes, 225
tobacco smoke constituents, 225–226
NOREPINEPHRINE
nicotine effects, 213, 215–216
smoking and plasma levels, 186
OBESITY
(See also BODY WEIGHT)
atherosclerosis and smoking interrelationships, 31, 46
cardiovascular disease risk factor, 206
CHD risk factor, 91, 92
lipoprotein level relationship, 96
stroke risk factor, 162
OCCUPATIONS
farm laborers, 133–134
grade of employment and CHD mortality, 110–111
industrial workers, 275–278, 280–282, 303, 314–315
nurses, 102
physicians, 65, 110, 112, 123–124, 164, 297
steelworkers, 111

381
INDEX

ORAL CONTRACEPTIVES
CHD risk factor with smoking, 101-104, 128
myocardial infarction and smoking interrelationships, 7
stroke risk factor with smoking, 166-171
subarachnoid hemorrhage and smoking interrelationships, 5, 8

PERIPHERAL VASCULAR DISEASE
animal studies, 189-190
atherosclerosis as underlying cause, 16
cessation of smoking effects, 190-192, 194
clinical investigations, 186-189
diagnosis, 179
epidemiologic studies, 182-186
reactivity of patient to tobacco glycoprotein, 56
risk factors, 180-182, 194
smoking effects, 8
treatment, 179-180

PERSONALITY
cardiovascular disease risk factor, 205
CHD risk factor, 91-93

PHYSICAL ACTIVITY
cardiovascular disease risk, 205
CHD risk, 91-92, 132
exercise tolerance and carbon monoxide exposure, 186
stroke incidence, 162
treatment of peripheral vascular disease, 179

PIPE SMOKERS
aortic lesions, 47, 194
CHD mortality effects, 8, 122
CHD risk, 86, 128
coronary event risk, 76-77
former cigarette smokers, 252
myocardial infarction risk, 88
peripheral vascular disease risk, 191
stroke mortality, 163
thiocyanate elevation, 244

PLATELETS
adhesiveness and carbon monoxide effects, 189-190
atherogenesis role, 217-219
nicotine effect in rabbits, 190
smoking effects, 6, 55-56, 187

PLATELETS—Contd
smoking effects in baboons, 190
thrombocytopenia as stroke risk factor, 186

PNEUMONIA
mortality trends, 334

PROSTAGLANDINS
nicotine effects and atherogenesis, 218-219

RACE FACTORS
aortic aneurysms and atherosclerosis, 194
atherosclerosis in aorta, 46
atherosclerosis in coronary arteries, 29, 31
atherosclerosis severity trends, 343-344
cardiovascular disease mortality trends, 331
cerebrovascular disease incidence, 170
CHD incidence, 77-79, 132-134
CHD mortality, 339
hypertensive disease mortality trends, 341
lipoprotein levels, 93
prevalence of smoking, 364-365
smoking patterns, 77
stroke mortality, 159, 165, 341

RECIDIVISM
rate following intervention trials, 201-203, 205

REDUCTION OF SMOKING
criteria for successful intervention, 245-247
intervention trial effects, 9, 256, 258, 262, 264, 270, 279-280, 309, 311-313, 315
peripheral vascular disease patients, 191

REFLEXES
nicotine effects, 213

REORGANIZED CHURCH OF JESUS CHRIST OF LATTER DAY SAINTS
mortality rates, 126

SATURATED FATS
(See also DIET)
consumption trends, 348
diet and atherogenesis, 19
lipoprotein composition relationship, 53
INDEX

SEVENTH DAY ADVENTISTS
CHD and cancer mortality, 126

SEX FACTORS
(See also WOMEN)
sortic aneurysm mortality, 194
brain infarction and myocardial infarction, 159
cessation attempts, 11, 373
CHD mortality, 110-113, 339
CHD mortality and smoking cessation trends, 348-352
CHD rates, 1
smoking pattern, 7
lipoprotein levels, 93
myocardial infarction incidence, 87-88
peripheral vascular disease prevalence, 184-185
stroke incidence, 165, 344
stroke mortality, 164
sudden cardiac death incidence, 68

SMOKING HABIT
prevalence trends, 336, 344, 346-350, 364-366, 373
Sweden, 111

SMOKING INTERVENTION TRIALS
cessation outcome, 9, 267-271, 281-291
community-based trials, 271-282, 314-318
individual clinical investigations, 248-271, 303-313, 318, 320
methodological problems, 244-249, 264-267, 280-281, 300-302

SMOKING PATTERNS
cessation rate effects, 261
CHD incidence, 81-83, 128
CHD mortality rates, 115, 115 119, 127
coronary event risk, 75-76
daily consumption trends, 373
intervention trial effects, 9
low yield cigarettes, 9
myocardial infarction incidence, 87-88
peripheral vascular disease relationship, 185
race factors, 77
reduction of smoking effects, 262
stroke mortality rates, 163-164, 171
sudden cardiac death risk, 7, 104
trends, 352

SMOKING PATTERNS—Contd.
women, 101-102, 104

SNUFF
intermittent claudication relationship, 186

SOCIOECONOMIC STATUS
CHD mortality rates, 111-112, 339, 350-352
CHD risk factor, 91
coronary atherosclerosis and smoking interrelationships, 33

STRESS
CHD risk factor, 91

STROKE
(See also CEREBROVASCULAR DISEASE)
atherosclerosis as underlying cause, 16
discharge rate trends, 344
incidence study, 344
mortality trends, 334, 340-341

SUDDEN CARDIAC DEATH
clinical manifestations, 68-69
risk factors, 104-105
smoking as risk factor in women, 102
smoking pattern relationship, 7, 128

TABS, TOBACCO
smoking behavior relationship, 371-372
tobacco smoke constituent, 227-228
yields in U.S. cigarettes, 228

THIOCYANATE
blood levels in smoking baboons, 190
serum levels and lipoproteins, 182
validation of self-reported smoking cessation, 244-246, 258, 261-265, 279-280, 305, 312

TOBACCO SMOKE
atherosclerosis pathogenesis, 48, 50-56
constituents, 8-9
physical and chemical characteristics, 206-209

TRIGLYCERIDES
atherosclerosis and plasma concentration, 181

CHD development and plasma levels, 84

CHD incidence, 92

383
INDEX

TRIGLYCERIDES—Contd.
elevation in peripheral vascular
disease, 180
nicotine effects, 219
stroke risk factor, 161, 165

VITAMIN D
arterial lesions in monkeys caused
by dietary excess, 50-51

WEIGHT GAIN
cessation of smoking correlation,
96-97, 301

WOMEN
(See also MENOPAUSE; ORAL
CONTRACEPTIVES; SEX
FACTORS)
brain infarction and LDL cholesterol, 162
cardiovascular disease mortality
trends, 331
CHD incidence, mortality, and
smoking interrelationships, 101-104, 127-128
subarachnoid hemorrhage risk and
smoking, 5, 167, 170

ZINC
tobacco smoke constituent, 227